![](https://investorshub.advfn.com/uicon/158678.png?cb=1661594561)
Tuesday, July 24, 2018 1:51:25 PM
Here are my comments and quotes:
"All I know is that he was the Ohr CEO for the first 14 months of the class period...the period during which the initial allegedly fraudulent statements were made. "
"I know that law firm has a reputation for um, aggressive and occasionally futile litigation, but the new CEO appears to be less than squeaky clean as well. Were they looking for one whose name ended in ", Defendant" or didn't it concern them?"
"But were all the non-defendant finds busy? Will he be able to focus on his CEO duties during the pendency of the case?"
"We are very excited by these promising interim results from this wet-AMD trial,"
said Dr. Irach B. Taraporewala, President and Chief Executive Officer of Ohr. "The
data further validate not only the clinical utility of non-invasive topical eye drop
therapies for macular and retinal disorders, but also the soundness of our company's
drug development science, and our proprietary formulation technologies that enable
topical dosing to achieve positive therapeutic effects in back-of-the-eye disorders.
These data give us a clear path for future registration studies, and we plan to discuss
Phase III registration study design and the path forward with the regulatory
authorities in the coming months."
1. Dr. Irach B. Taraporewala, President and Chief Executive Officer of Ohr was wrong with a capital W about the prospects for his drug yet was comfortable enough to assert some very positive qualities to the public about them...qualities that the trials didn't establish.
2. Ohr's stock totally fell apart when the public found out the truth about those prospects.
Haven't you had enough of being misled for the last bunch of years, whether it be done fraudulently and deceptively or simply by mistake or foolhardiness? The end result of those things has been the same for the share prices of both companies.
You don't have to like what I've said, but please try not to misunderstand or misrepresent it. Counting me as one of "those who I'm led to believe think the lawsuit has merit" does both of those things and I found it beneath you.
But can it core A apple?
Yes Ralph, of course it can core A apple.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM